Carisma stock jumps as Moderna deal lead to $2M (NASDAQ:CARM)
2024-06-28
rafal_olechowski Carisma Therapeutics (NASDAQ:CARM) climbed ~29% premarket Friday after the cell therapy developer said it would receive $2M for discovering a cancer drug candidate as part of a collaboration with Moderna (NASDAQ:MRNA). Nominating the first development candidate under the partnership, the company said that the unnamed drug targets Glypican-3, aContinue Reading